Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
Subscribe To Our Newsletter & Stay Updated
